Insmed Incorporated (INSM)

24.80 -0.12 (-0.48%) At close: 04:00PM EDT

Insmed Incorporated

700 US Highway 202/206
Bridgewater, NJ 08807
United States
908 977 9900
https://www.insmed.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 912

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. William H. Lewis J.D., M.B.A.	President, CEO & Chairman	1.59M	1.11M	1969
Ms. Sara M. Bonstein M.B.A.	Chief Financial Officer	810.4k	N/A	1981
Mr. Roger Adsett M.B.A.	Chief Operating Officer	1.01M	N/A	1969
Mr. John Drayton Wise M.B.A.	Chief Commercial Officer	888.85k	N/A	1975
Dr. Martina Flammer M.B.A., M.D.	Chief Medical Officer	872.29k	179.49k	1964
Mr. Brian K. Kaspar Ph.D.	Chief Scientific Officer	N/A	N/A	1974
Eleanor Barisser	Associate Director of Investor Relations	N/A	N/A	N/A
Mr. Michael Alexander Smith J.D.	Chief Legal Officer & Corporate Secretary	N/A	N/A	1978
Mandy Fahey	Executive Director of Corporate Communications	N/A	N/A	N/A
Ms. S. Nicole Schaeffer M.B.A.	Chief People Strategy Officer	660.81k	1.18M	1968

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Insmed Incorporated’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 9; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.